Who holds the patent on CRISPR?

The patent on CRISPR is a subject of complex dispute. Originally, the Broad Institute was granted a key patent on CRISPR-Cas9 gene editing in 2014, specifically for its use in eukaryotic cells. However, the University of California, Berkeley, where Jennifer Doudna and Emmanuelle Charpentier conducted their pivotal research, also filed for a patent. This led to a prolonged legal battle over the ownership of the CRISPR patent. Recently, there has been a surprising development in this dispute, with Doudna and Charpentier's team requesting the cancellation of their own European patents, citing inadequate explanation of CRISPR in their earliest patent applications. This move could potentially impact the commercial landscape of CRISPR technology.